Publicaciones (29) Publicaciones de HELENA BARRASA GONZÁLEZ

2024

  1. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods

    Scientific Reports, Vol. 14, Núm. 1

  2. Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms

    Heliyon, Vol. 10, Núm. 10

  3. Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 5, pp. 885-893

  4. Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach

    Antibiotics, Vol. 13, Núm. 6

2023

  1. Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study

    Blood Purification, Vol. 52, Núm. 5, pp. 464-473

  2. Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

    International Journal of Epidemiology, Vol. 52, Núm. 2, pp. 355-376

  3. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 5

2022

  1. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  2. Kidney Support in Sepsis

    The Sepsis Codex (Elsevier), pp. 169-176

  3. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

  4. Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units

    Medicina Intensiva, Vol. 46, Núm. 2, pp. 81-89

2021

  1. High rate of infections during ICU admission of patients with severe SARS-CoV-2 pneumonia: A matter of time?

    Journal of Infection

  2. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

  3. Pseudomonas aeruginosa susceptibility in spain: Antimicrobial activity and resistance suppression evaluation by pk/pd analysis

    Pharmaceutics, Vol. 13, Núm. 11

  4. Quantification of ceftaroline in human plasma using high‐performance liquid chromatography with ultraviolet detection: Application to pharmacokinetic studies

    Pharmaceutics, Vol. 13, Núm. 7

  5. Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort

    eLife

  6. The value of open-source clinical science in pandemic response: lessons from ISARIC

    The Lancet Infectious Diseases

2020

  1. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective

    International Journal of Infectious Diseases, Vol. 93, pp. 329-338

  2. Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation

    Pharmaceutics, Vol. 12, Núm. 1

  3. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria

    Anaesthesia Critical Care and Pain Medicine, Vol. 39, Núm. 5, pp. 553-561